Home

Articles from Velocity Clinical Research, Inc.

Velocity Clinical Research Partners with Verified Clinical Trials to combat double enrollment problem in clinical trials
DURHAM, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research, the leading multi-specialty clinical research organization, has partnered with Verified Clinical Trials (VCT) to set a new benchmark for patient safety and data quality in clinical trials through a new technological implementation at Velocity’s 80+ global sites.
By Velocity Clinical Research, Inc. · Via GlobeNewswire · January 30, 2025
Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director
DURHAM, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Velocity Clinical Research, the leading fully integrated clinical site organization, announces the appointment of Renata Berardocco as Executive Vice President and Managing Director for the Latin America (LATAM) region. Renata has nearly two decades of experience in senior leadership roles and joins from Fortrea, where she led Clinical Operations Delivery and Clinical Projects.
By Velocity Clinical Research, Inc. · Via GlobeNewswire · November 21, 2024
Velocity appoints ICON exec Rachael Buck Ph.D. as Head of U.K.
DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, today announces the appointment of Rachael Buck Ph.D. as Country Head in the U.K.
Velocity appoints ex-IQVIA and Science 37 Executive Mike Zaranek as CFO
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, today announces it has appointed Mike Zaranek as Chief Financial Officer (CFO). Reporting to Velocity President and CEO Paul Evans with immediate effect, Zaranek will direct the company’s financial goals and accounting, and advise on the Company’s strategic direction.
Velocity Clinical Research partners with Luminis Health, moves into oncology in the U.S.
DURHAM, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, and Luminis Health, a non-profit health system providing care for 1.8 million people, today announce their partnership to conduct clinical research within the health group’s organization, connecting more patients with community-based research programs.
nmible partners with Velocity Clinical Research to streamline clinical trials patient stipends
•  nmible’s solution expected to save more than 650 working days per year, administering payments
By Velocity Clinical Research, Inc. · Via GlobeNewswire · January 24, 2024
Velocity Clinical Research transforms patient experience and recruitment with VISION technology platform
• App downloads surpassed 25,000
By Velocity Clinical Research, Inc. · Via GlobeNewswire · January 9, 2024
Velocity expands to 17 sites in Europe
LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB Gesundheitsforschung Lübeck.
By Velocity Clinical Research, Inc. · Via GlobeNewswire · January 3, 2024
Velocity Clinical Research expands to Poland
LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. Located in Skierniewice, which is halfway between Warsaw and Lodz, the site marks the first in a series of key acquisitions targeted by the company in Poland by year's end.
By Velocity Clinical Research, Inc. · Via GlobeNewswire · December 6, 2023
Velocity aggressively expands MASH/MASLD capabilities with latest site acquisitions
• Add two KOLs: Dr Kris Kowdley and Dr Nadege Gunn
By Velocity Clinical Research, Inc. · Via GlobeNewswire · October 25, 2023
Velocity opens three U.K. greenfield clinical research sites
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it is opening greenfield clinical research sites in Bristol, Leicester, and Romford, demonstrating the company’s commitment to the U.K. market.
By Velocity Clinical Research, Inc. · Via GlobeNewswire · October 4, 2023
Velocity and Privia Health Enter Partnership to Embed Clinical Research Into Practice Sites
DURHAM, N.C., July 11, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, and Privia Health (Nasdaq: PRVA), a physician enablement company serving more than 3,700 providers and 4.4 million patients, today announced a partnership to open embedded clinical research sites within Privia’s practice network.
Velocity Clinical Research acquires Meridian Clinical Research creating largest global research sites business
DURHAM, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount. The deal makes Velocity the largest dedicated research site organization in the world with approximately 80 sites in the U.S. and Europe, including a tech hub in Hyderabad, India.
By Velocity Clinical Research, Inc. · Via GlobeNewswire · December 15, 2022
Velocity Clinical Research expands to UK
LONDON, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces its expansion into the U.K. with the acquisition of multi-site company Egin Research.
By Velocity Clinical Research, Inc. · Via GlobeNewswire · November 17, 2022
Velocity Clinical Research reveals findings from US patient survey on decentralization in clinical research
DURHAM N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading integrated research site organization with 40 locations across 19 U.S. states and Europe, today announces the findings of its U.S. patient survey, which aimed to better understand patient preference for study decentralization activities in clinical research.
By Velocity Clinical Research, Inc. · Via GlobeNewswire · September 28, 2022